Kromatid
Longmont
About Kromatid
KromaTiD focuses on advancing the knowledge of genetic abnormalities and diseases by developing molecular cytogenetics assays and reagents. It's molecular cytogenetic and GeneTracker assays discover, detect, and diagnose the range of disease-causing mutations - including inversions and translocations - in a single test. Based on Directional Genomic Hybridization (dGH), KromaTiD's assays generate the sequence, location, and orientation data from single cells, making them ideal for mixed cell population studies Co-founders Andrew Ray, Joel Bedford, Michael Cornforth, and Susan M. Bailey headquartered the company in Fort Collins, Colorado in 2007.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $28.1M
- Funding stage: Late Stage Venture
- Last round: Series C (Aug 2025)
- Website: kromatid.com
- Phone: 720-815-2898
Industries & Categories
Biotechnology, Developer Platform, Genetics, Medical
Social Profiles
Canonical: https://fsome.com/organization/kromatid-80140 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.